Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Toshitaka Sugawara

Concepts (131)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Pancreatic Neoplasms
22
2026
944
4.690
Why?
Carcinoma, Pancreatic Ductal
8
2025
297
2.460
Why?
Adenocarcinoma
8
2026
927
2.080
Why?
Pancreatectomy
12
2026
289
1.650
Why?
Neoadjuvant Therapy
9
2026
475
1.100
Why?
Hepatectomy
7
2026
256
1.020
Why?
CA-19-9 Antigen
2
2024
36
1.000
Why?
Adenocarcinoma, Mucinous
2
2025
76
0.910
Why?
Chemotherapy, Adjuvant
8
2026
429
0.770
Why?
Liver Neoplasms
9
2026
776
0.750
Why?
Carcinoma, Neuroendocrine
1
2023
38
0.740
Why?
Neuroendocrine Tumors
1
2023
122
0.670
Why?
Databases, Factual
4
2025
1493
0.640
Why?
Organ Transplantation
1
2023
244
0.590
Why?
Biliary Tract Surgical Procedures
2
2024
26
0.570
Why?
Biliary Fistula
1
2017
4
0.530
Why?
Bile
1
2017
26
0.530
Why?
Body Fluids
1
2017
70
0.510
Why?
Bilirubin
1
2017
101
0.510
Why?
Carcinoma, Hepatocellular
5
2019
370
0.510
Why?
Retrospective Studies
20
2026
17438
0.460
Why?
Antineoplastic Combined Chemotherapy Protocols
8
2026
1998
0.450
Why?
Neoplasm Recurrence, Local
7
2025
1160
0.410
Why?
Middle Aged
25
2026
36619
0.380
Why?
Aged
23
2026
26432
0.360
Why?
Neoplasm Staging
4
2025
1488
0.350
Why?
Prognosis
11
2024
4351
0.340
Why?
Proportional Hazards Models
2
2023
1331
0.280
Why?
Male
26
2026
73396
0.270
Why?
Humans
34
2026
146342
0.270
Why?
Survival Rate
8
2024
2092
0.250
Why?
Echinocandins
1
2026
8
0.240
Why?
Fungemia
1
2026
10
0.240
Why?
Mesenteric Artery, Superior
1
2026
28
0.230
Why?
Cohort Studies
5
2024
6077
0.230
Why?
Saccharomycetales
1
2026
31
0.230
Why?
Chyle
1
2025
4
0.230
Why?
Female
24
2026
79499
0.230
Why?
Colorectal Neoplasms
3
2020
874
0.230
Why?
Anastomotic Leak
1
2025
46
0.220
Why?
Neutropenia
1
2026
153
0.220
Why?
Postoperative Complications
4
2026
3034
0.220
Why?
Antifungal Agents
1
2026
153
0.220
Why?
Biomarkers, Tumor
2
2024
1339
0.220
Why?
Frozen Sections
1
2025
23
0.220
Why?
Diarrhea
1
2026
190
0.220
Why?
Organ Sparing Treatments
1
2024
37
0.210
Why?
Mesenteric Veins
1
2025
28
0.210
Why?
Biliary Tract Neoplasms
1
2024
30
0.200
Why?
Aged, 80 and over
8
2025
8391
0.200
Why?
Lymphatic Metastasis
2
2024
335
0.200
Why?
Pancreaticoduodenectomy
1
2025
149
0.200
Why?
Portal Vein
1
2025
123
0.200
Why?
Survival Analysis
2
2024
1378
0.190
Why?
Combined Modality Therapy
2
2023
1271
0.190
Why?
Preoperative Period
2
2021
157
0.190
Why?
Metastasectomy
1
2023
19
0.190
Why?
Area Under Curve
2
2021
335
0.190
Why?
Robotic Surgical Procedures
1
2026
210
0.190
Why?
ROC Curve
2
2021
617
0.170
Why?
Vascular Surgical Procedures
1
2025
352
0.170
Why?
Japan
4
2024
149
0.160
Why?
Gastroenterology
1
2023
187
0.160
Why?
Body Composition
1
2024
689
0.160
Why?
Pancreas
1
2023
343
0.160
Why?
Lymphocytes
1
2021
379
0.140
Why?
Indocyanine Green
1
2019
43
0.140
Why?
DNA Copy Number Variations
1
2020
192
0.140
Why?
Exome
1
2020
233
0.140
Why?
Kaplan-Meier Estimate
1
2021
970
0.140
Why?
Platelet Count
1
2018
95
0.140
Why?
Neoplasm, Residual
1
2019
143
0.130
Why?
Cefmetazole
1
2017
1
0.130
Why?
Risk Factors
5
2026
10921
0.130
Why?
Serum Albumin
1
2018
147
0.130
Why?
Follow-Up Studies
6
2024
5439
0.130
Why?
Fluorodeoxyglucose F18
1
2018
164
0.130
Why?
Adult
11
2025
41087
0.130
Why?
Hepatitis B, Chronic
1
2017
22
0.120
Why?
Treatment Outcome
7
2026
11821
0.120
Why?
Mutation
2
2020
4093
0.120
Why?
Drainage
1
2017
187
0.120
Why?
Positron-Emission Tomography
1
2018
343
0.120
Why?
Antibiotic Prophylaxis
1
2017
140
0.120
Why?
Prevalence
1
2023
2861
0.110
Why?
Viral Load
1
2018
526
0.110
Why?
Neutrophils
1
2021
1133
0.110
Why?
Hepatitis C
1
2018
251
0.110
Why?
Hepatitis C, Chronic
1
2017
150
0.110
Why?
Proto-Oncogene Proteins p21(ras)
1
2016
250
0.110
Why?
Leucovorin
2
2025
98
0.100
Why?
Models, Statistical
1
2018
669
0.100
Why?
Fluorouracil
2
2025
231
0.100
Why?
Incidence
3
2026
2936
0.090
Why?
Predictive Value of Tests
1
2017
2113
0.090
Why?
Lung Neoplasms
1
2023
2675
0.080
Why?
Disease-Free Survival
2
2023
778
0.070
Why?
Length of Stay
2
2026
1358
0.070
Why?
Tomography, X-Ray Computed
1
2018
2786
0.060
Why?
Postoperative Period
2
2018
355
0.060
Why?
Intention to Treat Analysis
1
2026
78
0.060
Why?
Operative Time
1
2026
195
0.060
Why?
Catheter-Related Infections
1
2026
101
0.050
Why?
Margins of Excision
1
2025
55
0.050
Why?
Microbial Sensitivity Tests
1
2026
367
0.050
Why?
Pancreatic Fistula
1
2024
35
0.050
Why?
Liver Cirrhosis
2
2017
278
0.050
Why?
Republic of Korea
1
2024
43
0.050
Why?
Anthropometry
1
2024
204
0.050
Why?
Radiotherapy, Adjuvant
1
2024
222
0.050
Why?
Forecasting
1
2023
388
0.040
Why?
Time Factors
2
2024
7109
0.040
Why?
Reproducibility of Results
2
2018
3416
0.040
Why?
Feasibility Studies
1
2024
1135
0.040
Why?
Adipose Tissue
1
2024
642
0.040
Why?
Risk Assessment
2
2019
3712
0.040
Why?
Prospective Studies
2
2024
8123
0.040
Why?
Ascites
1
2018
48
0.030
Why?
Statistics, Nonparametric
1
2019
426
0.030
Why?
Neoplasm Metastasis
1
2020
693
0.030
Why?
Radiopharmaceuticals
1
2018
210
0.030
Why?
Maryland
1
2017
67
0.030
Why?
Hepatitis
1
2017
43
0.030
Why?
Hepacivirus
1
2018
237
0.030
Why?
Neoplasm Invasiveness
1
2017
504
0.030
Why?
Imaging, Three-Dimensional
1
2019
582
0.030
Why?
Gene Expression Regulation, Neoplastic
1
2020
1432
0.020
Why?
Blood Transfusion
1
2017
394
0.020
Why?
Lung
1
2023
4122
0.020
Why?
Liver
1
2018
1864
0.020
Why?
United States
1
2025
16136
0.020
Why?
Sugawara's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)